人工智能赋能 打造全流程数智化眼健康服务体系 眼睛是人类感知世界的窗口，83%外界信息获取来自眼睛。眼健康不仅关乎生活质量，而且往往提示其他重大健康问题。 我国高度重视全民眼健康，将眼健康纳入全生命周期健康管理，重点保障儿童青少年、老年人等重点人群。然而，我国眼健康服务供给远未能满足人民群 众日益增长的需求。全国眼科医疗资源缺口巨大且优质资源多集中于大城市及大型医院。与此同时，我国近视防控形势严峻，过度使用电子设备也导致视 疲劳和干眼症等问题高发，加之人口老龄化进程加快及生活方式变化，眼底病患者数量持续攀升。 深圳市眼科医院在深圳市卫生健康委员会的支持下，率先探索人工智能眼健康服务的新路径。通过5G互联网，华南眼科智能诊疗数据中心已连通全国18 个省市的369家医疗卫生机构，让城市街区乃至偏远山村的居民，都能享受到及时、专业的眼科服务。 深圳市眼科医院院长迟玮表示："深圳是科技创新的城市，如何用高科技赋能满足湾区人民日益增长的眼健康需求，是时代给我们的命题。"深圳市眼科医 院依托在医教研与产业融合方面的长期积累，尤其是基于人工智能的三级诊疗模式前瞻布局，构建了集"依托深圳辐射湾区、全流程智能眼健康管理、家 校 ...

Core Viewpoint - Aibao Medical has signed a cooperation agreement with Hong Kong Polytechnic University to enhance collaboration in research and development, clinical translation, and talent cultivation in the field of ophthalmology [1][2] Group 1: Collaboration Details - The partnership aims to establish a long-term strategic collaboration mechanism, focusing on integrating industry resources and academic research advantages to improve the efficiency of research results and their implementation [1] - Both parties will work closely on myopia prevention and optical technology, leveraging their respective strengths to overcome key technological bottlenecks in the industry [1][2] Group 2: Talent Development and Innovation - Aibao Medical will provide research practice and internship opportunities through its ophthalmology scholarship, while the university will utilize its advantages in talent cultivation and global resources to create a joint training mechanism [2] - The collaboration will also explore cutting-edge technologies for myopia control in partnership with the university's startup, Tongyan Technology Co., Ltd., facilitating the industrialization of academic research outcomes [2] Group 3: Broader Impact - The agreement is seen as a new starting point for Aibao Medical, aiming to elevate Chinese ophthalmic technology to the international stage [2] - The collaboration is expected to serve as a model for Beijing-Hong Kong technology cooperation, enhancing technological exchanges and promoting industrial synergy between the two regions [2]

Core Viewpoint - The biopharmaceutical industry is at a significant historical juncture in 2025, balancing technological advancements with commercial rationality, and transitioning from "innovation-driven" to "value-driven" paradigms, while exploring sustainable growth paths amid dual tracks of the "Healthy China" strategy and global innovation landscape [1] Group 1: Company Strategy and Developments - Aier Eye Hospital Group has deepened its "1+8+N" strategy, enhancing its professional capabilities and humanistic approach, with a focus on making quality eye health services accessible to more people [7] - The company has released an AI strategy white paper, establishing a systematic layout for AI-assisted diagnosis and creating an "AI Digital Eye Hospital" for intelligent management of eye health services [8] - Aier is actively addressing the trends of myopia and population aging by strengthening specialized outpatient capabilities and constructing a comprehensive family eye health management system [8] Group 2: Clinical and Technological Advancements - The company has introduced several leading global diagnostic and treatment technologies, including the latest robotic femtosecond devices and the first domestically approved IGF-1R antibody drug [8] - Aier has successfully performed the first eye surgery robot-assisted retinal injection in Hunan, meeting the increasing demands for eye health services [8] - The organization is committed to its mission of ensuring eye health for all, regardless of socioeconomic status, by providing compassionate care and maintaining high standards in its services [9] Group 3: Future Directions - In 2026, Aier aims to focus on three main areas: innovation as a means to break through challenges, a dual-circulation strategy for international expansion, and leveraging technology to address clinical pain points [9][10] - The company plans to accelerate its AI technology development and digital eye care initiatives to enhance diagnostic efficiency and patient experience [9] - Aier emphasizes that technological advancements should prioritize patient-centered care, aiming to deepen the eye health ecosystem and integrate industry, academia, and research [9]

Core Viewpoint - The company, Guangzheng Eye Hospital, confirmed that it does not have any business involvement or investment in Hainan International Commercial Space Launch Co., Ltd. [2] Company Summary - Guangzheng Eye Hospital responded to an investor inquiry on an interactive platform regarding potential investments in Hainan International Commercial Space Launch Co., Ltd. [2]

Core Viewpoint - Huaxia Eye Hospital Group has been awarded the "2025 Innovation Brand Award" at the 8th Golden Jubilee Awards for its systematic, leading, and effective brand innovation practices [1][3] Group 1: Awards and Recognition - The "Golden Jubilee Award" is recognized for its objective, fair, and authoritative research attributes, based on big data analysis of thousands of companies [3] - This award follows Huaxia Eye's previous recognitions, including being listed in the "Top 50 New Brands" of the "China Listed Companies Brand Value List" and receiving accolades such as "Top Ten Trusted Health Brands" and "Outstanding Brand Management Company" [3] Group 2: Brand Innovation and Strategy - Brand innovation is essential for corporate growth and serves as a stabilizing force against market uncertainties [5] - Huaxia Eye integrates brand building into its "medical, education, and research" collaborative development system, enhancing brand connotation and soft power [5] - The company is implementing a "1236" strategy to accelerate the establishment of a world-renowned ophthalmology center and global service network by 2025 [5] Group 3: Technological Advancements - Huaxia Eye has introduced advanced technologies such as the new generation of robotic all-laser LASIK VISUMAX800 and the SMILE pro minimally invasive surgery, becoming one of the first clinical application units for EVO+ ICL (V5) in China [6] - The company has completed the localized deployment of the DeepSeek model and launched the first domestic AI self-test tool for dry eyes, enhancing eye health management [6] Group 4: Social Responsibility and Community Engagement - The company has initiated various social responsibility programs, including the "Eye Health Care Plan for Journalists" and the publication of the first "Xiamen City Journalists Eye Health White Paper" [6] - Huaxia Eye's "Huaxia Bright Action" charity brand has conducted medical assistance in countries along the "Belt and Road" and provided support in regions like Ningxia, Qinghai, Xinjiang, and Tibet [7] Group 5: Future Outlook - Huaxia Eye aims to continue its commitment to innovation and patient-centered care, contributing significantly to the development of the ophthalmology sector in China [9]

今天，记者在湖南省县级公立医院眼科能力提升建设项目2025年度总结会上获悉，2021年10月至今，通 过该项目的落地，96家医院开展新技术，独立眼科由原来的3家增加到21家，14家医院设置眼科（含在 五官科内），63家医院新增眼底相机，我省基层眼科服务能力明显提升。 "针对前期调研发现我省基层医疗机构眼科缺人、缺设备、缺眼底病诊疗能力，导致很多老百姓在当地 无法得到及时诊治的情况，我们改变传统帮扶模式，通过AI赋能，利用项目经费为基层医疗机构提供 眼底相机，建立一分钟快速识别眼底病变和全身慢病的预警机制，在保障医疗服务水平的同时极大解决 了基层眼科医生匮乏和能力不足的问题。"湘雅二医院项目负责人罗静教授介绍，项目已累计完成AI辅 助阅片和远程会诊4万余人次，指导基层开展眼科手术300余台，使群众在县域内即可获得专家级诊疗方 案。我省"人工智能辅助诊断系统在基层致盲性眼病筛查中的作用"入选国家卫生健康委适宜技术推广备 选库。 会上 ，来自桃源县中医医院、石门县人民医院、祁阳市人民医院、湘乡市人民医院、慈利县中医医 院、新宁县人民医院、宁乡市中医医院、隆回县人民医院等优秀项目单位代表，围绕学科建设路径、人 才梯队 ...

转自：汕头发布 20多年来，汕头国际眼科中心坚持"授人以渔"，通过"医疗技术输出"探索出"汕眼模式"，为基层眼科发展开辟一条可持续、可复制的帮扶之路。 白内障超声乳化手术是目前治疗白内障最主流的手术方式之一，在西藏尚未普及。去年底，西藏自治区藏医院眼科医生旺姆来到汕头国际眼科中心进修， 希望将这项技术带回高原，让家乡患者获得更清晰、稳定的视力。"我本是藏医出身，眼科基础比较薄弱。"旺姆医生说，"在这里通过模拟训练和手术视 频学习，掌握了器械使用等关键技能，对开展手术更有信心了。" 以医联体之"通" 破解患者看病之"痛" 在"走出去"的同时，汕头国际眼科中心也通过"建体系"实现持续赋能。该中心引入"互联网+"理念，组建涵盖63家单位的医联体网络，搭建远程医疗平 台，开展手术带教、疑难病例会诊、远程阅片、远程培训等项目，推动基层眼科医疗水平同质化发展。 "我们在西藏、新疆、宁夏、甘肃、河南、广西、云南等地都有众多医联体合作点。"张铭志教授说，"我们响应'健康中国'号召，通过互联网远程进行理论 培训和疑难病会诊，再结合线下定期派驻医生实地指导、解决难题，形成了线上线下联动的独特模式，系统性地助力基层眼科振兴。" 截 ...

Core Viewpoint - He Eye Hospital has confirmed that recent shareholder reduction actions were conducted in compliance with legal regulations and are based on the shareholders' own financial needs, emphasizing respect for shareholders' rights and market choices [1] Group 1: Shareholder Actions - The company stated that shareholders have fulfilled their information disclosure obligations regarding the reduction of shares [1] - The reduction actions are driven by the shareholders' independent financial decisions [1] Group 2: Company Strategy - He Eye Hospital will continue to focus on long-term value creation while enhancing internal operational efficiency and core service capabilities [1] - The company aims to adapt to global technological innovations and economic development trends by exploring and promoting sustainable public health service models in the ophthalmology sector [1] - The commitment to social responsibility and corporate value is highlighted, with a focus on safeguarding the long-term interests of all shareholders [1]

Core Viewpoint - The company is committed to high-quality long-term development and is actively advancing its "1+8+N" strategy to enhance its diagnostic and treatment network capabilities, providing multi-level ophthalmic medical services for all age groups, which drives continuous business growth [1]. Group 1 - The company emphasizes the importance of building a digital and intelligent ophthalmology system [1]. - The strategic focus is on enhancing the diagnostic and treatment network capabilities [1]. - The company aims to provide comprehensive ophthalmic medical services for all age groups [1].

Core Viewpoint - The company maintains international synchronization and domestic leadership in refractive technology, advocating the principle that "the best is what suits" while offering personalized and precise medical services [1] Group 1: Technological Advancements - The company has introduced various upgraded surgical techniques in the past two years, including ICLV5, all-laser femtosecond Pro, all-laser femtosecond 4.0, and all-light plastic surgery, to meet diverse patient needs [1] - The all-laser femtosecond Pro technique, introduced in mid-2025, achieved a cumulative surgical volume of over 10,000 cases by January 2026, accounting for approximately 25% of the total in the domestic market [1] - The company is a significant promoter and contributor to the all-light plastic surgery technique, enhancing patient experience with shorter surgery times and better visual quality [1] Group 2: Competitive Advantages - The company leverages its network, expert, brand, and popular science advantages to accelerate the promotion of new technologies, reinforcing its first-mover advantage in the domestic ophthalmology market [1] - The company plays a multiplicative role for upstream manufacturers, which is challenging to achieve in fragmented markets [1]